Living Medical Textbook - Osteoporosis - Projects In Knowledge - Fracture Prevention and Therapeutic Management Edition Table of Contents - Treatment of Osteoporosis CME Information

Chapter 4 – Treatment of Osteoporosis

Contributing Editor
	Paul D. Miller, MD Distinguished Clinical Professor of Medicine University of Colorado Medical Center Colorado Center for Bone Research Lakewood, Colorado	Jeri W. Nieves, PhD Associate Professor of Clinical Epidemiology Mailman School of Public Health Columbia University New York, New York

top

Activity Goal
The goal of this CME/CE activity is to address gaps in competence and practice performance by:

Stressing the importance of early screening and diagnosis of patients with or at risk for developing osteoporosis and fractures
Identifying the pathways involved in the pathophysiology of osteoporosis and fractures
Providing updates on current and emerging therapies with regard to mechanism of action, efficacy, safety, treatment regimen requirements for compliance, and their role in providing fracture prevention/reduction

Target Audience
This activity is designed for primary care physicians, including internists, family practitioners, gynecologists, and other clinicians involved in the care of patients with or at risk of developing osteoporosis and fractures.

Learning Objectives

•	Evaluate pharmacologic treatment options for postmenopausal women and men age 50 years and older who meet criteria for osteoporosis treatment established by the National Osteoporosis Foundation.
•	Assess nonpharmacologic interventions to be included in an overall management plan for patients receiving pharmacologic treatment for osteoporosis.

top

CME Information: Physicians
Statement of Accreditation
Projects In Knowledge^® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Projects In Knowledge designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CE Information: Nurses
Projects In Knowledge^® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.

This activity is approved for 1.21 nursing contact hour(s).

DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, CBRN, or PIK endorsement of any commercial product or service.

CE Information: Pharmacists

Projects In Knowledge^® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This chapter is worth up to 2.00 contact hours (0.2 CEUs). The ACPE Universal Program Number assigned to this application activity is 0052-0000-09-202-H01-P.

top

Disclosure Information
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

Paul D. Miller, MD, has received grant/research support from Amgen Inc, Eli Lilly and Company, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Procter & Gamble Pharmaceuticals, Roche Pharmaceuticals, and sanofi-aventis; and is a consultant for and/or on the advisory board of Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, NPS Pharmaceuticals Inc, Procter & Gamble Pharmaceuticals, Roche Pharmaceuticals, and sanofi-aventis.

Jeri W. Nieves, PhD, has received honoraria from Sciele Pharma, Inc; and has received consulting fees from Bayer Pharmaceuticals Corporation and Merck & Co, Inc.

PLANNING COMMITTEE

Jeffrey P. Levine, MD, MPH, is on the speakers bureau of Merck & Co, Inc and Procter & Gamble; on the advisory board of Amgen Inc, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, and Wyeth Pharmaceuticals. Dr. Levine will be referencing unlabeled/unapproved uses of drugs or products in his activities.

Marjorie M. Luckey, MD, is on the speakers bureau for Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Procter & Gamble, and sanofi-aventis; has received consulting fees from Amgen, Inc and Novartis Pharmaceuticals Corporation.

Ethel S. Siris, MD, is on the speakers bureau for Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Procter & Gamble, and sanofi-aventis; has received consulting fees from Amgen, Inc, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Procter & Gamble, and sanofi-aventis.

Gloria A. Bachmann, MD, is a consultant for and has received grant/research support from Astellas Pharma Inc, Bayer Group, Bionovo Inc, Boehringer-Ingelheim GmbH, Boston Scientific Corporation, Covance Inc, Duramed Pharmaceuticals, Inc, Femme Pharma Inc, Glaxo Smith Kline, Inc, Hoffmann-La Roche Inc, Hormos Medical, Johnson and Johnson Services, Inc, Merck and Company, Inc, Novartis Pharmaceuticals Corporation, Novo Nordisk, Inc, Procter & Gamble, Inc, QuatRx Pharmaceuticals Co., Wyeth Pharmaceuticals Inc, and Xanodyne Pharmaceuticals, Inc.

Cheryl L. Lambing, MD, is on the advisory board of Amgen Inc.

E. Michael Lewiecki, MD, FACP, FACE, has received grant/research support from Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc, Procter & Gamble, Hoffmann-La Roche Inc, sanofi-aventis, and Wyeth; is on the speakers bureau of Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation; on the advisory board of Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche Inc, Novartis Pharmaceuticals Corporation, Upsher-Smith Laboratories Inc, and Wyeth; is a direct stock shareholder with General Electric, Procter & Gamble, and Teva Pharmaceuticals; is on the board of directors of International Society for Clinical Densitometry.

Nancy J. Nordenson, MT (ASCP), MFA , has no significant relationships to disclose.

This activity will include a discussion of estrogen, which is not approved for the treatment of osteoporosis, as well as a discussion of strontium ranelate, bazedoxifene, denosumab, and odanacatib, which are not approved for either the prevention or treatment of osteoporosis.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge’s staff members have no significant relationships to disclose.

top

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Contract for Mutual Responsibility in CME/CE

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

For more information on the contract, click here

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.

top

1892.04